➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 19, 2021

DrugPatentWatch Database Preview

Litigation Details for Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc. (S.D.N.Y. 2013)

Date Filed Document No. Description Snippet Link To Document
2014-11-21 101 validity of U.S. Patent No. 7,851,482 (“’482 patent”), U.S. Patent No. 8,309,122 (“‘122 patent”) and U.S. …validly construed claim of U.S. Patent No. 7,851,482 (“the ‘482 patent”) either literally or under the…filed this lawsuit asserting U.S. Patent No. 7,851,482 (“the ‘482 patent”) against Roxane with knowledge… Declaring that the patent claims in United States Patent No. 7,851,482 are invalid for failure … (Noninfringement of U.S. Patent No. 7,851,482) 2. The manufacture, use, sale External link to document
2015-03-05 112 7, and 9 of U.S. Patent No. 8,114,383 (“the ’383 patent”). Those same ‘383 patent claims have been the…to be tried with respect to Endo’s ‘482 patent and ‘383 patent. We write to provide Your Honor with the…instituted by the Patent & Trademark Office (“PTO”) in connection with that patent. Those proceedings… claims of the ‘482 Patent. See Exs. 1 and 2 hereto. Cancelled patent claims cannot be asserted…claims 1, 2, 5, and 7 of the ’383 patent, and the only ‘383 patent claim that Plaintiffs will assert External link to document
2015-03-09 126 application which later issued as U.S. Patent No. 8,309,122 (“the ‘122 patent”) at issue in this litigation. …that apply to the ‘122 patent and to U.S. Patent No. 8,329,216 (“the ‘216 patent”) in suit here. Those…and the same or related Endo patent applications that led to the patents-in-suit. In In re Kao… of a decision of the U.S. Patent and Trademark Office’s Board of Patent Appeals and Interferences (“…upheld the patent office’s determination that the pending claims of certain of Endo’s patent applications External link to document
2015-03-12 134 . Patent No. 7,276,250 (“‘250 patent”) . 3 ….................................3 U.S. Patent No. 7,276,250.........................................… † U,S. Patent No. 5,958,456 (“‘456 patent”), U.S. Patent No. 5,662,933 (“‘933 patent”), and U.S. …Roxane on three additional patents: the ‘482 patent, ‘122 patent, and ‘216 patent, claiming that Roxane’s…formulation of Opana® ER: the ‘933 patent, ’456 patent, and ’250 patent†—none of which are currently involved External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.